tiprankstipranks
Trending News
More News >
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market

NewAmsterdam Pharma Company (NAMS) AI Stock Analysis

Compare
191 Followers

Top Page

NA

NewAmsterdam Pharma Company

(NASDAQ:NAMS)

Rating:58Neutral
Price Target:
$19.00
▲(2.32%Upside)
The overall stock score reflects significant positive corporate events and developments in clinical trials, offset by financial performance challenges and valuation concerns. While technical analysis suggests potential medium-term strength, the company's financial challenges and unprofitable status weigh on its valuation.
Positive Factors
Alzheimer's Disease
Obicetrapib's positive Alzheimer's biomarker data from the Ph. 3 BROADWAY trial could represent a significant new therapeutic opportunity that is underappreciated at current stock levels.
Market Opportunity
There is a substantial commercial opportunity afforded by the broad, accelerating physician preference for the comprehensive LDL+ profile of obi.
Research and Development
NewAmsterdam hosted a comprehensive R&D day event that reinforced obicetrapib's differentiated 'LDL+' clinical profile, indicating potential patient benefits beyond lowering LDL-C.
Negative Factors
Competition
MRK's positive Ph. 3 data helps validate the oral PCSK9 inhibitor space and signals new competition, but also potentially future market expansion growth, in the CVRR landscape.
Historical Setbacks
Despite historical setbacks in the CETPi class, obicetrapib and PREVAIL are considered fundamentally different and highly de-risked.

NewAmsterdam Pharma Company (NAMS) vs. SPDR S&P 500 ETF (SPY)

NewAmsterdam Pharma Company Business Overview & Revenue Model

Company DescriptionNewAmsterdam Pharma Company (NAMS) is a clinical-stage biopharmaceutical company focused on the research and development of transformative therapies to address cardiovascular diseases. The company operates within the biopharmaceutical sector, leveraging advanced scientific research to create novel treatments. Its core products include investigational therapies aimed at managing and preventing cardiovascular conditions, with a primary focus on dyslipidemia and other metabolic disorders.
How the Company Makes MoneyNAMS primarily makes money through the development and commercialization of its proprietary drug candidates. The company's revenue model is centered around successful clinical trials that lead to regulatory approval, allowing it to either license its therapies to larger pharmaceutical companies or directly market them. Key revenue streams include milestone payments from licensing agreements, potential royalty payments from commercialized products, and partnerships with other pharmaceutical companies for co-development and co-marketing efforts. These partnerships provide significant financial support and shared resources, contributing to the company's earnings as it advances its product pipeline.

NewAmsterdam Pharma Company Financial Statement Overview

Summary
The company shows strong revenue growth but struggles with profitability due to high R&D expenses. The balance sheet is robust with low leverage, yet negative cash flows indicate ongoing cash burn, typical for the biotech industry.
Income Statement
45
Neutral
The company's revenue has shown significant volatility with periods of growth and decline. The gross profit margin is 100% due to no cost of goods sold, but the net profit margin is low due to high operating expenses. EBIT and EBITDA margins are negative, indicating operational challenges. Revenue growth from 2023 to 2024 is strong, but the company has not achieved profitability.
Balance Sheet
60
Neutral
The company maintains a strong equity position with an equity ratio of 87.6%, indicating low leverage. Debt-to-equity is minimal at 0.06, suggesting low financial risk. However, the company has reported consecutive net losses, impacting return on equity, which remains negative.
Cash Flow
55
Neutral
Operating cash flow is consistently negative, highlighting cash burn issues typical in the biotechnology industry. Free cash flow growth is negative, indicating increased outflows. However, ample financing cash flow suggests the company is able to raise capital successfully, mitigating immediate liquidity concerns.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue47.14M45.56M12.76M95.91M0.000.00
Gross Profit47.14M45.56M12.76M95.91M0.000.00
EBITDA-255.78M-241.49M-176.86M-3.31M-30.73M-5.43M
Net Income-187.36M-241.60M-176.94M-21.14M-36.71M-5.75M
Balance Sheet
Total Assets818.41M864.62M347.10M531.58M59.78M9.23M
Cash, Cash Equivalents and Short-Term Investments808.48M834.19M340.45M438.52M53.09M7.86M
Total Debt389.00K448.00K60.00K118.00K164.00K11.65M
Total Liabilities41.05M107.12M58.70M47.06M9.99M12.81M
Stockholders Equity777.36M757.50M288.39M484.52M49.79M-3.58M
Cash Flow
Free Cash Flow-86.55M-159.24M-141.24M7.96M-25.18M-5.98M
Operating Cash Flow-136.75M-158.56M-141.22M7.97M-25.16M-5.97M
Investing Cash Flow-59.40M-62.85M-24.00K715.00K-20.00K-13.00K
Financing Cash Flow467.53M659.51M8.91M375.18M68.99M11.32M

NewAmsterdam Pharma Company Technical Analysis

Technical Analysis Sentiment
Negative
Last Price18.57
Price Trends
50DMA
18.66
Negative
100DMA
19.49
Negative
200DMA
20.22
Negative
Market Momentum
MACD
-0.13
Positive
RSI
47.17
Neutral
STOCH
23.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAMS, the sentiment is Negative. The current price of 18.57 is below the 20-day moving average (MA) of 19.24, below the 50-day MA of 18.66, and below the 200-day MA of 20.22, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 47.17 is Neutral, neither overbought nor oversold. The STOCH value of 23.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAMS.

NewAmsterdam Pharma Company Risk Analysis

NewAmsterdam Pharma Company disclosed 90 risk factors in its most recent earnings report. NewAmsterdam Pharma Company reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

NewAmsterdam Pharma Company Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$1.84B12.0524.71%20.62%14.08%
65
Neutral
¥345.58B10.59-2.88%2.65%11.80%-6.84%
58
Neutral
$2.08B-31.51%
56
Neutral
$2.04B-86.10%29.32%-11.00%
51
Neutral
$1.64B-70.58%100.03%64.22%
45
Neutral
$2.05B-35.21%-100.00%-144.79%
40
Underperform
$3.00B
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NAMS
NewAmsterdam Pharma Company
18.11
-2.19
-10.79%
DNLI
Denali Therapeutics
13.99
-7.75
-35.65%
ARQT
Arcutis Biotherapeutics
14.02
4.72
50.75%
HRMY
Harmony Biosciences Holdings
31.60
1.60
5.33%
RXRX
Recursion Pharmaceuticals
5.06
-2.10
-29.33%
MTSR
Metsera, Inc.
28.45
0.65
2.34%

NewAmsterdam Pharma Company Corporate Events

Product-Related AnnouncementsPrivate Placements and FinancingBusiness Operations and Strategy
NewAmsterdam Pharma Schedules R&D Day for June 2025
Positive
Jun 11, 2025

NewAmsterdam Pharma Company announced a Research & Development Day event scheduled for June 11, 2025, in New York City, aimed at analysts and investors. The event will be webcast live, with a replay available for 30 days. The company has been active in clinical trials, with significant developments in its BROOKLYN, BROADWAY, and TANDEM Phase 3 studies, and has secured funding to support a potential U.S. commercial launch. The company’s product candidate, Obicetrapib, shows promise in addressing cardiometabolic diseases, and there are ongoing efforts to explore its therapeutic potential in Alzheimer’s disease and multi-infarct dementia.

The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
NewAmsterdam Pharma Announces Positive Phase 3 Trial Results
Positive
Jun 9, 2025

On June 9, 2025, NewAmsterdam Pharma announced positive topline data from their Phase 3 BROADWAY clinical trial, which evaluated the effects of obicetrapib on Alzheimer’s Disease biomarkers. The study showed statistically significant reductions in the primary outcome measure of p-tau217 in both the full study population and ApoE4 carriers, suggesting a potential preventive strategy for Alzheimer’s Disease. These findings highlight the potential of CETP inhibition in mitigating Alzheimer’s risk and further differentiate obicetrapib as a uniquely effective therapy addressing multiple health concerns, including cardiovascular and neurodegenerative diseases.

The most recent analyst rating on (NAMS) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

Executive/Board ChangesShareholder Meetings
NewAmsterdam Pharma Approves Key Proposals at AGM
Neutral
Jun 6, 2025

On June 4, 2025, NewAmsterdam Pharma Company N.V. held its annual general meeting where 74.45% of eligible shares voted. Shareholders approved several proposals, including the adoption of the 2024 annual accounts, discharge of directors’ liabilities, appointment of Deloitte as auditor, and various board appointments. The company also decided to hold annual Say-on-Pay votes until 2031.

The most recent analyst rating on (NAMS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
NewAmsterdam Pharma Presents Promising Phase 3 Trial Data
Positive
May 7, 2025

On May 7, 2025, NewAmsterdam Pharma announced additional data from its BROADWAY and TANDEM Phase 3 clinical trials, presented at the European Atherosclerosis Society Congress and published in leading medical journals. The data demonstrated significant reductions in LDL-C levels and improvements in cardiovascular biomarkers with the use of obicetrapib, both as monotherapy and in combination with ezetimibe, highlighting its potential as a foundational therapy in CVD management. The trials showed a 45% reduction in lipoprotein(a) and a 21% reduction in major adverse cardiovascular events, reinforcing obicetrapib’s promise as an effective oral treatment for CVD.

Executive/Board ChangesBusiness Operations and Strategy
NewAmsterdam Pharma Appoints Adele Gulfo to Board
Positive
Apr 17, 2025

On April 15, 2025, NewAmsterdam Pharma appointed Adele Gulfo as an independent director to its Board of Directors, a strategic move as the company prepares for the potential launch of its drug obicetrapib next year. Gulfo’s extensive experience in pharmaceutical leadership and her history of successful drug launches are expected to significantly contribute to NewAmsterdam’s commercial strategy and infrastructure development, enhancing its position in the cardiovascular treatment market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 18, 2025